Figure 1.
Phase 1 EXPLORER Study: Avapritinib effects on measures of mast cell burden. Waterfall plots are shown for bone marrow mast cell burden, serum tryptase level, spleen volume, and KIT D816V variant allele fraction. A, other antineoplastic therapy; M, prior midostaurin exposure; MAF, mutant allele fraction; VAF, variant allele fraction.